The association between the pathogenesis of benign prostatic hyperplasia (BPH) and inflammation has recently received attention. We previously showed that not only the inflammation response pathway, but also the classical complement pathway is activated in BPH tissue from model rats with stroma-dominant BPH. The classical complement pathway is activated by autoantigens that recognize immune complexes and it is responsible for various diseases via a mechanism that amplifies inflammation. We postulated that immune complexes amplify inflammation through complement activation, which leads to prostatic proliferation. Therefore, we expressed complement factors, analyzed their functions, and identified autoantigens to understand the pathogenic mechanism of BPH.
INTRODUCTION AND OBJECTIVES:
The association between the pathogenesis of benign prostatic hyperplasia (BPH) and inflammation has recently received attention. We previously showed that not only the inflammation response pathway, but also the classical complement pathway is activated in BPH tissue from model rats with stroma-dominant BPH. The classical complement pathway is activated by autoantigens that recognize immune complexes and it is responsible for various diseases via a mechanism that amplifies inflammation. We postulated that immune complexes amplify inflammation through complement activation, which leads to prostatic proliferation. Therefore, we expressed complement factors, analyzed their functions, and identified autoantigens to understand the pathogenic mechanism of BPH.
METHODS: Fetal urogenital sinus (UGS) isolated from male 20-day-old rat embryos was implanted into the ventral prostate of pubertal male rats to create rat models of BPH. Complement factors were expressed and functionally analyzed in BPH tissues, and then serum concentrations of IgG and the expression of complement factors in BPH tissues were assessed. We immunoprecipitated BPH protein using an anti-IgG antibody to identify antigens, and analyzed the protein by mass spectrometry after SDS-PAGE separation. The expression of complement factors in human BPH tissue was also analyzed.
RESULTS: The expression of complement factors C1q, C3, MBL, factor B, and MAC was significantly up-regulated in tissues from BPH rats compared with those from normal rats (p<0.01). The classical complement pathway was initially activated, followed by an alternative complement pathway activated in BPH. These complement factors were also up-regulated mostly in stromal areas of human BPH. The serum IgG concentration was significantly increased (398.1 ng/mL, p<0.01) in rat BPH and IgG was deposited in stromal areas of the BPH. Mass spectrometry of IgG binding protein identified annexin, Hsp90, and b-actin as antigens of immunocomplexes.
CONCLUSIONS: We clarified that the immune system is responsible for the development of BPH. Complement pathway activation by immunocomplexes recognizing annexin, Hsp90, and b-actin as autoantigens might be responsible for the pathogenesis of BPH. Inflammation is the most prevalent and widespread histological finding in the human prostate, and associates with the development and progression of benign prostatic hyperplasia. Several factors have been hypothesized to cause inflammation, yet the role each plays in the etiology of prostatic inflammation remains unclear. This study investigated a role for the common protozoan parasite Toxoplasma gondii in prostatic inflammation and established a novel mouse model. METHODS: Male mice were infected intraperitoneally with green fluorescent protein (GFP)-expressing T. gondii parasites and prostatic infection was confirmed with parasite specific staining and GFP localization. The resulting prostatic inflammation was scored on severity and focality of infiltrating leukocytes and epithelial hyperplasia. We characterized inflammatory cells with flow cytometry and the resulting epithelial proliferation with bromodeoxyuridine (BrdU) incorporation. In addition, human sera from T. gondii IgG seropositive and seronegative male patients were tested for total prostate specific antigen (PSA) concentrations by ELISA.
RESULTS: We found that T. gondii infects the mouse prostate during systemic infection and can establish parasite cysts that persist for at least 60 days. T. gondii infection induces a substantial and chronic inflammatory reaction in the mouse prostate characterized by monocytic and lymphocytic inflammatory infiltrate. T. gondii-induced inflammation results in reactive hyperplasia, involving basal and luminal epithelial proliferation, and the exhibition of microglandular hyperplasia in 60 day inflamed mouse prostates. Finally, T. gondii seropositive men have 5.08 times the odds of having an elevated PSA level (>4.0 ng/ml) than age-matched seronegative men.
CONCLUSIONS: We found that T. gondii infects the mouse prostate during systemic infection and can establish parasite cysts that persist for at least 60 days. T. gondii infection induces a substantial and chronic inflammatory reaction in the mouse prostate characterized by monocytic and lymphocytic inflammatory infiltrate. T. gondii-induced inflammation results in reactive hyperplasia, involving basal and luminal epithelial proliferation, and the exhibition of microglandular hyperplasia in 60 day inflamed mouse prostates. Finally, T. gondii seropositive men have 5.08 times the odds of having an elevated PSA level (>4.0 ng/ml) than age-matched seronegative men.
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MP17-06 THYROID HORMONES AND BENIGN PROSTATIC HYPERPLASIA
Jun Ho Lee*, Young Bin Kim, Gyeong Eun Min, Dong-Gi Lee, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: Thyroid hormones play an important role in cell differentiation, growth, and metabolism. Several investigators have documented the role of thyroid hormones in the development of prostate cancer. However, to date there are only limited data available regarding thyroid hormone levels in benign prostatic hyperplasia (BPH).
METHODS: A total of 5708 men aged 40 to 59 years who had participated in a health examination were included in the study. Lower urinary tract symptoms (LUTS)/BPH were assessed by international prostate symptom score (IPSS), prostate volume, maximal flow rate (Qmax), and a full metabolic workup. Serum levels of thyroid-stimulating hormone (TSH) and free thyroxine (T4) were measured using chemiluminescence immunoassay by commercial kits. We divided participants into quartiles based on their TSH and free T4 levels: first quartile, Q1; second quartile, Q2; third quartile, Q3; and fourth quartile, Q4. We then investigated their relationship using the chi-squared test, the Cochran-Armitage trend test, logistic regression analyses, and a propensity score matched case-control study.
RESULTS: The mean age of the study group was 51.1 AE 5.2 years, and the mean free T4 and median TSH were 1.05 AE 0.14 and 1.44 (0.96-2.13)ng/mL, respectively. In addition, the ratio of metabolic syndrome and low testosterone (<3.5 ng/mL) were 41.9% and 11.8%, respectively. There was a significant increase in the percentage of men with IPSS>7, Qmax<10 mL/sec, and prostate volume !30 mL, with increase of free T4 quartile (IPSS>7(%): Q1:57.2, Q2:56.7, Q3:60.3, Q4:62.5, P¼.001; Qmax<10 mL/sec(%): Q1:3.5, Q2:3.2, Q3:4.1, Q4:4.8, P¼.038; total prostate volume !30 mL(%): Q1:15.2, Q2:16.4, Q3:18.0, Q4:19.3, P¼.002). After adjusting for age, body mass index, testosterone, and metabolic syndrome, the odds ratio for prostate volume !30 mL of free T4 Q3 and free T4 Q4 were significantly higher than free T4 Q1 [odds ratio; 5-95 percentile interval), P value; Q1:.000 (references); Q2:1.140(.911-1.361), P¼.291; Q3:1.260 (1.030-1.541), P¼.025; Q4:1.367(1.122-1.665), P¼.002]. After adjusting for age, body mass index, testosterone, metabolic syndrome, and prostate volume, the odds ratio for IPSS>7 of free T4 Q4 were significantly higher than that of free T4 Q1 (odds ratio (5-95 percentile interval), P value; Q1:.000 (references); Q2:.969 (.836-1.123), P¼.677; Q3:1.123 (.965-1.308), Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e213
